Qiagen (NYSE:QGEN) Issues FY 2024 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its FY 2024 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 2.100- for the period, compared to the consensus estimate of 2.110. The company issued revenue guidance of $2.0 billion-, compared to the consensus revenue estimate of $2.0 billion. Qiagen also updated its FY24 guidance to at least $2.10 EPS.

Qiagen Trading Down 1.0 %

Shares of NYSE QGEN traded down $0.41 during trading on Thursday, hitting $42.40. 403,784 shares of the company traded hands, compared to its average volume of 1,217,944. The company has a 50-day moving average price of $42.56 and a 200-day moving average price of $42.71. The company has a quick ratio of 1.62, a current ratio of 1.99 and a debt-to-equity ratio of 0.24. Qiagen has a 1 year low of $34.74 and a 1 year high of $47.70. The firm has a market capitalization of $9.68 billion, a P/E ratio of 28.71, a P/E/G ratio of 3.58 and a beta of 0.42.

Qiagen (NYSE:QGEN) last issued its earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. The business had revenue of $459.00 million for the quarter, compared to analyst estimates of $453.91 million. Qiagen had a net margin of 17.38% and a return on equity of 12.50%. The company’s revenue for the quarter was down 5.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.53 EPS. On average, equities analysts predict that Qiagen will post 2.09 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on QGEN. Morgan Stanley upgraded shares of Qiagen from an equal weight rating to an overweight rating and upped their price target for the company from $49.48 to $51.00 in a research report on Friday, February 16th. Citigroup dropped their target price on shares of Qiagen from $61.86 to $60.00 and set a buy rating on the stock in a report on Thursday, February 8th. JPMorgan Chase & Co. boosted their price objective on shares of Qiagen from $50.00 to $52.00 and gave the stock an overweight rating in a report on Thursday, February 8th. Finally, Stifel Nicolaus dropped their price objective on shares of Qiagen from $55.00 to $45.00 and set a hold rating on the stock in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $50.95.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.